AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus
Oral recombinant methioninase has high potential to slow or arrest infection of 2019-nCoV in patients, with and without symptoms, said Dr. Qinghong Han, methioninase project leader at AntiCancer.